colorectal tumor
Conditions
Interventions
Aspirin (100 mg/day) enteric-coated tablet
Placebo tablet / day
Sponsors
Basic and clinical researches on the development of chemopreventive drugs
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Candidate patients have to meet all the following inclusion criteria to participate in the study. # Patients with at least one colorectal tumor (intramucosal cancer and adenoma) as confirmed by histological diagnosis, all of which have been removed endoscopically (at any time) # Patients with known history of all endoscopic treatments (including histological diagnosis) of colorectal tumors # Patients who have undergone total colonoscopy at least twice # Patients with clean colon as confirmed by total colonoscopy within 3 months before the study
Exclusion criteria
Exclusion criteria: # Patients with a medical history of submucosal or deeper colorectal cancer. # Patients currently taking antithrombotics such as Bayaspirin, Bufferin, Panaldine, Warfarin and Persantin. # Patients who have undergone colorectal resection (those who have undergone appendectomy are allowed to participate in the study). # Patients with familial colorectal adenoma. # Patients with a history of treatment of gastric or duodenal ulcer (those with successful eradication of Helicobacter pylori and ulcer resolution at S2 are allowed to participate in the study) # Patients with bleeding tendency, a platelet count of 150,000, or with abnormal PT # Patients with any existing cancer at the time of participation in the study. # Patients with known allergy to aspirin. # Patients currently taking anticancer drugs. # Women who are or may be pregnant during the study period. # Patients currently taking NSAIDs at least 3 times weekly, for example, as a analgesic.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Only the occurrence of a colorectal tumor (adenoma or cancer) is selected as the primary endpoint. | — |
Countries
Japan
Contacts
Public ContactHideki Ishikawa
Kyoto Prefectural University of Medicine Department of Molecular-Targeting Cancer Prevention
Outcome results
None listed